DEXCOM INC
DXCMNASDAQ🏆 #332 by market capEarnings Oct 28US Equity
$926.94▼ $52.09 (−5.62%)
Simulated price1h—
24h▼ 5.6%
7d—
14d—
30d—
1y—
🏦Market Cap
$33.08B
Mid Cap
📈Revenue Growth (YoY)
+15.5%
Healthy
📊Gross Margin
64.3%
High
💵FCF Margin
28.3%
Strong
⚖️P/S Ratio
6.5x
Fair
Otter Score
45
Weak
No chart data available for DXCM.
Trading Snapshot
- Day Range
- $920.78 – $942.14
- 52-Week Range
- $54.11 – $88.18
- Volume
- $2.66B
- Avg Volume
- $2.72B
- Shares Outstanding
- 385.9M
- Next Earnings
- Sep 14, 2026
Fundamentals Snapshot
- Annual Revenue
- $5.06B
- Last Q Revenue
- $1.39B
- P/E Ratio
- 32.5
- P/S Ratio
- 6.5x
- EPS (TTM)
- $2.51
- Dividend Yield
- —
Why Investors Own DXCM
- ✓High-growth profile — revenue up +38.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 76% gross margin and 8% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$5.06B▲ +38.8% YoY
Gross Margin (TTM)
75.6%▲ +1.6% YoY
Operating Income (TTM)
$1.26B▲ +38.8% YoY
Free Cash Flow (TTM)
$380M▲ +38.8% YoY
About DEXCOM INC
A company profile for DEXCOM INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
45/100
Analyst Price Target
ⓘAverage Target
$1,177.95
▲ +27.1% Upside
High Target$1,479.50
Low Target$921.43
Based on 16 analysts
Latest News & Updates
🚀
Reuters·2h ago
DEXCOM INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
MarketWatch·5h ago
Analysts lift DXCM price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Bloomberg·1d ago
DEXCOM INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.